Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients

BACKGROUND: Low-dose tacrolimus-based immunosuppression is a standard therapy in kidney and liver transplantation; however, the optimal therapeutic level of tacrolimus has not been established in lung transplantation. We aimed to identify the tacrolimus level associated with better outcomes in lung...

Full description

Bibliographic Details
Main Authors: Jung-Hwa Ryu, Sunmi Choi, Hyun Joo Lee, Young Tae Kim, Young Whan Kim, Jaeseok Yang
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Annals of Thoracic Medicine
Subjects:
Online Access:http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2019;volume=14;issue=3;spage=186;epage=191;aulast=Ryu
id doaj-de62eb4104dd4fdfa83cfe78e8663a1e
record_format Article
spelling doaj-de62eb4104dd4fdfa83cfe78e8663a1e2020-11-24T23:53:20ZengWolters Kluwer Medknow PublicationsAnnals of Thoracic Medicine1817-17371998-35572019-01-0114318619110.4103/atm.ATM_160_18Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patientsJung-Hwa RyuSunmi ChoiHyun Joo LeeYoung Tae KimYoung Whan KimJaeseok YangBACKGROUND: Low-dose tacrolimus-based immunosuppression is a standard therapy in kidney and liver transplantation; however, the optimal therapeutic level of tacrolimus has not been established in lung transplantation. We aimed to identify the tacrolimus level associated with better outcomes in lung transplant patients. METHODS: This retrospective study included patients who underwent lung transplantation at Seoul National University Hospital between 2006 and 2016. Kaplan–Meier survival analysis and Cox regression were performed according to tacrolimus levels at several time-points within 1-year posttransplantation. RESULTS: A total of 43 patients received bilateral lung transplantation. The median age was 53 years and the median follow-up was 20.5 months. Overall and 1-year patient survival rates were 55.8% and 74.4%, respectively. Infection was the most common cause of death (78.9%). Chronic lung allograft dysfunction was observed in 16.3%. A tacrolimus level <9 ng/ml at 1 month was associated with lower rejection-free survival (P = 0.009). A time-averaged tacrolimus level <10 ng/ml within 1 month posttransplantation was an independent risk factor for poor patient survival (hazard ratio: 4.904; 95% confidence interval: 1.930–12.459; P= 0.001). Furthermore, higher tacrolimus levels did not increase infectious complications. CONCLUSIONS: These finding suggest that tacrolimus levels ≥10 ng/ml within 1 month after lung transplantation appear to be associated with better patient survival.http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2019;volume=14;issue=3;spage=186;epage=191;aulast=RyuChronic lung allograft dysfunctionlung transplantationrejectionsurvivaltacrolimus
collection DOAJ
language English
format Article
sources DOAJ
author Jung-Hwa Ryu
Sunmi Choi
Hyun Joo Lee
Young Tae Kim
Young Whan Kim
Jaeseok Yang
spellingShingle Jung-Hwa Ryu
Sunmi Choi
Hyun Joo Lee
Young Tae Kim
Young Whan Kim
Jaeseok Yang
Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients
Annals of Thoracic Medicine
Chronic lung allograft dysfunction
lung transplantation
rejection
survival
tacrolimus
author_facet Jung-Hwa Ryu
Sunmi Choi
Hyun Joo Lee
Young Tae Kim
Young Whan Kim
Jaeseok Yang
author_sort Jung-Hwa Ryu
title Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients
title_short Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients
title_full Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients
title_fullStr Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients
title_full_unstemmed Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients
title_sort low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients
publisher Wolters Kluwer Medknow Publications
series Annals of Thoracic Medicine
issn 1817-1737
1998-3557
publishDate 2019-01-01
description BACKGROUND: Low-dose tacrolimus-based immunosuppression is a standard therapy in kidney and liver transplantation; however, the optimal therapeutic level of tacrolimus has not been established in lung transplantation. We aimed to identify the tacrolimus level associated with better outcomes in lung transplant patients. METHODS: This retrospective study included patients who underwent lung transplantation at Seoul National University Hospital between 2006 and 2016. Kaplan–Meier survival analysis and Cox regression were performed according to tacrolimus levels at several time-points within 1-year posttransplantation. RESULTS: A total of 43 patients received bilateral lung transplantation. The median age was 53 years and the median follow-up was 20.5 months. Overall and 1-year patient survival rates were 55.8% and 74.4%, respectively. Infection was the most common cause of death (78.9%). Chronic lung allograft dysfunction was observed in 16.3%. A tacrolimus level <9 ng/ml at 1 month was associated with lower rejection-free survival (P = 0.009). A time-averaged tacrolimus level <10 ng/ml within 1 month posttransplantation was an independent risk factor for poor patient survival (hazard ratio: 4.904; 95% confidence interval: 1.930–12.459; P= 0.001). Furthermore, higher tacrolimus levels did not increase infectious complications. CONCLUSIONS: These finding suggest that tacrolimus levels ≥10 ng/ml within 1 month after lung transplantation appear to be associated with better patient survival.
topic Chronic lung allograft dysfunction
lung transplantation
rejection
survival
tacrolimus
url http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2019;volume=14;issue=3;spage=186;epage=191;aulast=Ryu
work_keys_str_mv AT junghwaryu lowearlyposttransplantserumtacrolimuslevelsareassociatedwithpoorpatientsurvivalinlungtransplantpatients
AT sunmichoi lowearlyposttransplantserumtacrolimuslevelsareassociatedwithpoorpatientsurvivalinlungtransplantpatients
AT hyunjoolee lowearlyposttransplantserumtacrolimuslevelsareassociatedwithpoorpatientsurvivalinlungtransplantpatients
AT youngtaekim lowearlyposttransplantserumtacrolimuslevelsareassociatedwithpoorpatientsurvivalinlungtransplantpatients
AT youngwhankim lowearlyposttransplantserumtacrolimuslevelsareassociatedwithpoorpatientsurvivalinlungtransplantpatients
AT jaeseokyang lowearlyposttransplantserumtacrolimuslevelsareassociatedwithpoorpatientsurvivalinlungtransplantpatients
_version_ 1725470291700744192